Skip to main content

ADMINISTRACION INTRATUMORAL Y DIANIZADA DE AGENTES DE INMUNOTERAPIA PARA EL TRATAMIENTO DEL CANCER

SAF2017-83267-C2-1-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PARA LA INVESTIGACION MEDICA APLICADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8

  • Andrea, Carlos de
  • Ochoa, M. Carmen
  • Villalba-Esparza, María
  • Teijeira, Álvaro
  • Schalper, Kurt A.
  • Abengozar-Muela, Marta
  • Eguren-Santamaría, Iñaki
  • Sáinz, Cristina
  • Sánchez-Gregorio, Sandra
  • Garasa, Saray
  • Ariz Galilea, Mikel
  • Ortiz de Solórzano, Carlos
  • Rodríguez Ruiz, María
  • Pérez Gracia, José Luis
  • Lozano, María Dolores
  • Echeveste, José I.
  • Sanmamed, Miguel F.
  • Melero, Ignacio
Neutrophil extracellular traps (NETs) are webs of extracellular nuclear DNA extruded by dying neutrophils infiltrating tissue. NETs constitute a defence mechanism to entrap and kill fungi and bacteria. Tumours induce the formation of NETs to the advantage of the malignancy via a variety of mechanisms shown in mouse models. Here, we investigated the presence of NETs in a variety of human solid tumours and their association with IL-8 (CXCL8) protein expression and CD8+ T-cell density in the tumour microenvironment. Multiplex immunofluorescence panels were developed to identify NETs in human cancer tissues by co-staining with the granulocyte marker CD15, the neutrophil marker myeloperoxidase and citrullinated histone H3 (H3Cit), as well as IL-8 protein and CD8+ T cells. Three ELISA methods to detect and quantify circulating NETs in serum were optimised and utilised. Whole tumour sections and tissue microarrays from patients with non-small cell lung cancer (NSCLC; n = 14), bladder cancer (n = 14), melanoma (n = 11), breast cancer (n = 31), colorectal cancer (n = 20) and mesothelioma (n = 61) were studied. Also, serum samples collected retrospectively from patients with metastatic melanoma (n = 12) and NSCLC (n = 34) were ELISA assayed to quantify circulating NETs and IL-8. NETs were detected in six different human cancer types with wide individual variation in terms of tissue density and distribution. At least in NSCLC, bladder cancer and metastatic melanoma, NET density positively correlated with IL-8 protein expression and inversely correlated with CD8+ T-cell densities. In a series of serum samples from melanoma and NSCLC patients, a positive correlation between circulating NETs and IL-8 was found. In conclusion, NETs are detectable in formalin-fixed human biopsy samples from solid tumours and in the circulation of cancer patients with a considerable degree of individual variation. NETs show a positive association with IL-8 and a trend towards a negative association with CD8+ tumour-infiltrating lymphocytes., This project has been supported by grants from the I-ON program from Bristol-Myers Squibb, Partners of Choice Network from AstraZeneca, MINECO SAF2017-83267-C2-1-R (AEI/FEDER, UE) and Instituto de Salud Carlos III and co-financed by Fondos FEDER. This project has also received funding from the European Union's Horizon 2020 Research and Innovation Program (grant agreement no. 635122 - PROCROP), Fundación de la Asociación Española Contra el Cancer (AECC) and Cancer Research UK (Accelerator Project: Local Radioimmunotherapy). AT has received financial support through 'la Caixa' Banking Foundation (LCF/BQ/LR18/11640014). COS has received financial support through the Spanish Ministry of Science, Innovation and Universities, under grants RTI2018-094494-B-C22 and RTC-2017-6218-1 (MCIU/AEI/FEDER, UE). MFS is supported by a Miguel Servet contract from Instituto de Salud Carlos III, Fondo de Investigacion Sanitaria (Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

  • Compte, Marta
  • Lykke Harwood, Seandean
  • Muñoz, Inés G.
  • Navarro, Rocío
  • Zonca, Manuela
  • Pérez-Chacón, Gema
  • Erce-Llamazares, Ainhoa
  • Merino, Nekane
  • Tapia-Galisteo, Antonio
  • Cuesta, Ángel M.
  • Mikkelsen, Kasper
  • Nuñez-Prado, Natalia
  • Aznar, Maria A.
  • Lykkemark, Simon
  • Martínez Torrecuadrada, Jorge Luis
  • Melero, Ignacio
  • Blanco, Francisco J.
  • Bernardino de la Serna, Jorge
  • Zapata, Juan M.
  • Sanz, Laura
  • Álvarez-Vallina, Luis
The costimulation of immune cells using first-generation anti-4-1BB monoclonal antibodies (mAbs) has demonstrated anti-tumor activity in human trials. Further clinical development, however, is restricted by significant off-tumor toxicities associated with FcγR interactions. Here, we have designed an Fc-free tumor-targeted 4-1BB-agonistic trimerbody, 1D8N/CEGa1, consisting of three anti-4-1BB single-chain variable fragments and three anti-EGFR single-domain antibodies positioned in an extended hexagonal conformation around the collagen XVIII homotrimerization domain. The1D8N/CEGa1 trimerbody demonstrated high-avidity binding to 4-1BB and EGFR and a potent in vitro costimulatory capacity in the presence of EGFR. The trimerbody rapidly accumulates in EGFR-positive tumors and exhibits anti-tumor activity similar to IgG-based 4-1BB-agonistic mAbs. Importantly, treatment with 1D8N/CEGa1 does not induce systemic inflammatory cytokine production or hepatotoxicity associated with IgG-based 4-1BB agonists. These results implicate FcγR interactions in the 4-1BB-agonist-associated immune abnormalities, and promote the use of the non-canonical antibody presented in this work for safe and effective costimulatory strategies in cancer immunotherapy., This study was supported by grants from the European Union [IACT Project (602262), iNEXT Project (1676) and a Marie Curie Career Integration Grant (PCIG13-GA-2013-618914)], the Ministerio de Economía y Competitividad (CTQ2017-83810-R, RTC-2016-5118-1, SAF2017-83267-C2-1-R, SAF2017-89437-P, and PTQ-16-08340), the Fondo de Investigación Sanitaria/Instituto de Salud Carlos III (PI16/00357 and PI16/00895), the UK Research and Innovation (18130023), and the Danish Council for Independent Research (DFF-6110-0053). The CIC bioGUNE is a Severo Ochoa Center of Excellence (Ministerio de Economia y Competitividad award SEV-2016-0644). This study was also funded by FEDER., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs

  • Zapata, Juan M.
  • Pérez-Chacón, Gema
  • Carr-Baena, Pablo
  • Martinez-Forero, Ivan
  • Azpilikueta, Arantza
  • Otano, Itziar
  • Melero, Ignacio
CD137 (4-1BB, Tnsfr9) is a member of the TNF-receptor (TNFR) superfamily without known intrinsic enzymatic activity in its cytoplasmic domain. Hence, akin to other members of the TNFR family, it relies on the TNFR-Associated-Factor (TRAF) family of adaptor proteins to build the CD137 signalosome for transducing signals into the cell. Thus, upon CD137 activation by binding of CD137L trimers or by crosslinking with agonist monoclonal antibodies, TRAF1, TRAF2, and TRAF3 are readily recruited to the cytoplasmic domain of CD137, likely as homo- and/or heterotrimers with different configurations, initiating the construction of the CD137 signalosome. The formation of TRAF2-RING dimers between TRAF2 molecules from contiguous trimers would help to establish a multimeric structure of TRAF-trimers that is probably essential for CD137 signaling. In addition, available studies have identified a large number of proteins that are recruited to CD137:TRAF complexes including ubiquitin ligases and proteases, kinases, and modulatory proteins. Working in a coordinated fashion, these CD137-signalosomes will ultimately promote CD137-mediated T cell proliferation and survival and will endow T cells with stronger effector functions. Current evidence allows to envision the molecular events that might take place in the early stages of CD137-signalosome formation, underscoring the key roles of TRAFs and of K63 and K48-ubiquitination of target proteins in the signaling process. Understanding the composition and fine regulation of CD137-signalosomes assembly and disassembly will be key to improve the therapeutic activities of chimeric antigen receptors (CARs) encompassing the CD137 cytoplasmic domain and a new generation of CD137 agonists for the treatment of cancer., Funding was from Instituto de Salud Carlos III (ISCIII) (PI16/00895 to JZ), Ministerio de Economía y Competitividad (MINECO) RTC-16-5118-1 to JZ and IM, SAF 2014-52361-R and SAF 2017-83267-C2-1R to IM; and Cancer Research Institute (CRI) CLIP Grant 2017, Asociación Española Contra el Cancer, Fundación BBVA and I-ON Network-BMS to IM. The cost of this publication was paid in part by funds from the European Fund for Economic and Regional Development (FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

  • Teijeira, Alvaro
  • Garasa, Saray
  • Gato, María
  • Alfaro, Carlos
  • Migueliz, Itziar
  • Cirella, Assunta
  • Andrea, Carlos de
  • Ochoa, Maria Carmen
  • Otano, Itziar
  • Etxeberria, Iñaki
  • Andueza, María Pilar
  • Nieto, Celia P.
  • Resano, Leyre
  • Azpilikueta, Arantza
  • Allegretti, Marcello
  • Pizzol, María de
  • Ponz-Sarvisé, Mariano
  • Rouzaut, Ana
  • Sanmamed, Miguel F.
  • Schalper, Kurt
  • Carleton, Michael
  • Mellado, Mario
  • Rodriguez-Ruiz, María E.
  • Berraondo, Pedro
  • Perez-Gracia, Jose L.
  • Melero, Ignacio
Extrusion of neutrophil extracellular traps (NETs) constitutes an adhesive mechanism employed by polymorphonuclear leukocytes in microbial defense and plays a role in cancer metastasis. Teijeira et al. show that intratumoral NETs protect malignant cells against cytotoxic attacks of the immune system, such as those elicited by checkpoint-based immunotherapy.Neutrophils are expanded and abundant in cancer-bearing hosts. Under the influence of CXCR1 and CXCR2 chemokine receptor agonists and other chemotactic factors produced by tumors, neutrophils, and granulocytic myeloid-derived suppressor cells (MDSCs) from cancer patients extrude their neutrophil extracellular traps (NETs). In our hands, CXCR1 and CXCR2 agonists proved to be the major mediators of cancer-promoted NETosis. NETs wrap and coat tumor cells and shield them from cytotoxicity, as mediated by CD8 T cells and natural killer (NK) cells, by obstructing contact between immune cells and the surrounding target cells. Tumor cells protected from cytotoxicity by NETs underlie successful cancer metastases in mice and the immunotherapeutic synergy of protein arginine deiminase 4 (PAD4) inhibitors, which curtail NETosis with immune checkpoint inhibitors. Intravital microscopy provides evidence of neutrophil NETs interfering cytolytic cytotoxic T lymphocytes (CTLs) and NK cell contacts with tumor cells., This project was supported by MINECO SAF2017-83267-C2-1-R (AEI/FEDER, UE) (Ignacio Melero) and the immuno-oncology network of Bristol-Myers Squibb (I-ON). This project received funding from the European Union’s Horizon 2020 research and innovation program (grant agreement 635122 - PROCROP) and Fundación de la Asociación Española Contra el Cáncer (AECC). A.T. has received financial support through “la Caixa” Banking Foundation (LCF/BQ/LR18/11640014).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

  • González-Vaz, Javier
  • Azpilikueta, Arantza
  • Ochoa, Maria Carmen
  • Olivera, Irene
  • Gomis, Gabriel
  • Cirella, Asunta
  • Luri-Rey, Carlos
  • Álvarez, Maite
  • Perez-Gracia, Jose L.
  • Ciordia, Sergio
  • Eguren-Santamaria, Iñaki
  • Alexandru, Raluca
  • Berraondo, Pedro
  • Andrea, Carlos de
  • Teijeira, Alvaro
  • Corrales, Fernando J.
  • Zapata, Juan M.
  • Melero, Ignacio
CD137 (4-1BB) is a member of the TNFR family that mediates potent T cell costimulatory signals upon ligation by CD137L or agonist monoclonal antibodies (mAbs). CD137 agonists attain immunotherapeutic antitumor effects in cancer mouse models, and multiple agents of this kind are undergoing clinical trials. We show that cIAP1 and cIAP2 are physically associated with the CD137 signaling complex. Moreover, cIAPs are required for CD137 signaling toward the NF-κB and MAPK pathways and for costimulation of human and mouse T lymphocytes. Functional evidence was substantiated with SMAC mimetics that trigger cIAP degradation and by transfecting cIAP dominant-negative variants. Antitumor effects of agonist anti-CD137 mAbs are critically dependent on the integrity of cIAPs in cancer mouse models, and cIAPs are also required for signaling from CARs encompassing CD137’s cytoplasmic tail., I.M. has been granted with PID2020-112892RB funded by MICIN/AEI/10.13039/501100011033 and SAF2017-83267-C2-1-R funded by MICIN/AEI/10.13039/501100011033/ and by FEDER “Una manera de hacer Europa,” (HR21-00083) the Fundación La Caixa, “MINCITH. Metabolic requirements for immune INfiltration in effective Cancer ImmunoTHerapy” “AYUDAS FUNDACIÓN BBVA A EQUIPOS DE INVESTIGACIÓN CIENTÍFICA 2019” Fundación BBVA, the Instituto de Salud Carlos III (PI20/00002 and PI19/01128), cofinanced by the Fondos FEDER “A way to make Europe” and Joint Translational Call for Proposals 2015 (JTC 2015), TRANSCAN456 2 (code TRS-2016-00000371), and the Gobierno de Navarra Proyecto LINTERNA (reference 0011-1411-2020-000075). Funding was also received from B. J. Baselga (Fundación FERO) and the T2-EVOLVE project from the EU. I.M. and M.A. receive grant funding from Pharmamar and Highlight Therapeutics. M.A. is supported by AECC (INVES1904ALVA). J.M.Z. has been granted with PID2019-110405RB-I00 funded by MICIN/AEI/10.13039/501100011033 and with P2022/BMD-7225 funded by Consortium in Biomedicine of Comunidad de Madrid., Peer reviewed